To better risk stratify patients, using baseline characteristics, to help optimise decision-making for men with moderate-tosevere lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) through a secondary analysis of the Medical Therapy of Prostatic Symptoms (MTOPS) trial.
Introduction
BPH can progress over time. Community based studies have estimated that >30% of men will experience clinical progression in the course of 5 years [1] [2] [3] [4] , predominantly characterised by increases in LUTS severity [5, 6] . While BPH is highly prevalent, not all men with BPH have the same risk for progression [7, 8] .
Determining predictors of this risk has been an ongoing process over the past decade. A few trials have examined their placebo arms to elucidate baseline characteristics that portend worse prognoses [9, 10] . However, these efforts have generally focused on a single factor, such as initiation of 5α-reductase inhibitors (5-ARIs), for men with enlarged prostates or elevated PSA levels. In clinical practice, this may translate into focusing on an isolated variable to risk stratify when patients have multiple factors that might simultaneously influence the risk of progression and the potential benefits of therapy.
With the combined use of α-blockers and 5-ARIs, men can reduce their risk of BPH progression and ultimate need for invasive procedures. The Medical Therapy of Prostatic Symptoms (MTOPS) trial demonstrated clear benefit in risk reduction with this medical combination [6] . Classically, clinical trials showing a positive result suggest that practitioners should adopt a 'treat all' strategy. Yet, just as patient risk of progression can be variable, a given patient's response to medical therapy may diverge from the mean, a concept known as heterogeneity of treatment effect. to examine the relative and absolute effects across different risk strata, as baseline risk is a mathematical determinant of the treatment effect and can differ greatly across patients in a trial [11] [12] [13] . To date, it remains unknown how the benefits of available therapies for BPH vary across patients at different progression risks, and such information could have important implications for clinical practice.
To better aid clinicians with decision making, we sought to risk stratify men with moderate-to-severe LUTS secondary to BPH using established risk factors in a data-driven model. With data from the MTOPS, we examined trial outcomes across risk strata of BPH progression to better define which patients are most likely to benefit from α-blockers, 5-ARIs, or their combination.
Patients and Methods
We obtained original, publicly available data from the MTOPS study. The MTOPS study was conducted by the MTOPS Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Approval for our present analysis was provided by NIDDK and the study was approved by the Tufts Medical Center Internal Review Board [14] . The design, rationale, and outcomes of the MTOPS study are described in detail elsewhere [6] . In short, MTOPS was a randomised trial evaluating doxazosin, finasteride, or the combination of these medications for risk of BPH progression in men aged ≥50 years with AUA Symptom Index (AUA-SI) scores of 8-30 and maximum urinary flow rates (Qmax) of 4-15 mL/s enrolled between 1993 and 1998. BPH progression, or the primary outcome, was defined as 'the first occurrence of an increase over base line of at least four points in the AUA-SI score, acute urinary retention, renal insufficiency, recurrent urinary tract infection, or urinary incontinence' [6].
To capture potential variables for risk stratification, we reviewed the current literature. Within their primary analysis, MTOPS investigators found that baseline PSA level and baseline prostate volume significantly correlated with progression in univariate analysis [6] . We identified two other models predictive of BPH progression based on: i) randomised-controlled trials with a different 5-ARI (dutasteride) [8, 15] and ii) expert consensus [16] . These revealed additional potential risk factors: age, severe symptoms (as defined by both the BPH Impact Index (BII) [17] and the AUA-SI [18]; Appendix 1), lower Qmax, and elevated post-void residual urine volume (PVR). Review of other community based surveys and placebo-controlled trials further supported the relevance of these variables [1, 2, [19] [20] [21] [22] [23] .
Using Cox proportional hazards regression, we conducted univariate tests to determine which of these variables, measured at baseline, were associated with the outcome. We then used the factors with P-values <0.1 in a multivariate Cox model, excluding treatment assignment. As the GP does not typically assess PVR or Q max in a primary care setting, we attempted to make our work more broadly applicable by creating a reduced model with easily measured factors (age, PSA level, AUA-SI, BII). The full and reduced Cox models were internally validated with bootstrapping to quantify optimism in model performance. We evaluated model performance with the c-statistic [24] . Calibration was evaluated with a calibration plot and modified Hosmer-Lemeshow chi-squared test for survival analysis [25] and was excellent (chi-squared P = 0.99).
From both the full and reduced Cox regression models, in separate analyses, we stratified the trial population into equal-sized risk quartiles. Within each risk quartile, we calculated the active drug treatment effect compared with placebo for each of the three intervention arms (i.e., doxazosin, finasteride, combination). Using Kaplan-Meier estimated failure rates after 4 years of follow-up, we calculated the absolute risk reduction and number needed to treat for each drug or drug combination compared with placebo, as well as the combined therapy compared with each active drug individually. Heterogeneity of treatment effect was assessed by including an interaction term in the Cox regression model between the baseline linear risk predictor and treatment assignment to estimate the effect of treatment as a function of risk in BPH progression.
Finally, with results from the internally validated models, we constructed a clinical decision tool (nomogram) for care providers. Data management and regression model building were performed using SAS version 9.3 (SAS Institute, Cary NC). We used Frank Harrell's 'rms' package in R software version 3.0.1 to perform the bootstrapped internal validation and generate the nomogram.
Results
In all, 3047 men were followed in MTOPS for a mean of 4.5 years. They were randomised to four arms: placebo (737 men), doxazosin (756), finasteride (768), and combined therapy (786). In all, 351 primary outcome events (i.e., BPH progression events) occurred in total, with 128 in the placebo arm, 85 in the doxazosin arm, 89 in the finasteride arm, and 49 in the combination arm. These were predominantly characterised as increases in symptom severity (78%), but did include acute urinary retention (12%), incontinence (9%), and recurrent UTI/urosepsis in five cases. The 4-year overall risk of clinical progression within the placebo arm was 17%, compared with 10% in the doxazosin arm, 10% in finasteride arm, and 5% in combined therapy arm (all previously reported P-values <0.002) [6] . Baseline characteristics of the study patients are shown in Table 1 . Because collection of the variables of interest was excellent, we used complete case analysis and excluded only nine subjects from the full multivariate model and four from the reduced multivariate model.
Bivariate analysis was performed on all clinically relevant variables based on our literature review (Table 2) . Variables showing statistical significance were then used to create a parsimonious, multivariable model of BPH progression risk.
Baseline BII score (per 1 point, hazard ratio [HR] 1.12, 95% CI 1.07-1.17), PVR (per 100 mL, HR 1.17, 95% CI 1.04-1.30), serum PSA level (per 5 ng/mL, HR 1.44, 95% CI 1.14-1.82), age (per 10 years, HR 1.33, 95% CI 1.15-1.53), AUA-SI score (per 5 points, HR 0.76, 95% CI 0.68-0.85), and Qmax (per 5 mL/s, HR 0.74, 95% CI 0.60-0.90) were found to be significantly negatively correlated with overall BPH progression in multivariable analysis (Table 3) . Internal This predictive model of risk for BPH progression (c-statistic = 0.635) showed varying risks of progression across quartiles (Fig. 1) . Formal tests of interaction between risk and treatment were not significant (data not shown), indicating that patients experienced roughly proportional benefits across risk strata from the three different treatments. However, the highest-risk quartile had a risk of progression ≈300% that of the lowest within all trial arms on the absolute risk reduction scale. Thus, the number needed to treat for those patients in the lowest quartile of risk was about three-times that for patients in the highest quartile. MTOPS showed a 17% overall incidence of clinical progression for the 'average' patient [6] , but a patient within the lowest quartile only bears a progression risk of 10.7%, while the typical highest quartile patient faces up to a 29.6% risk of progression. To facilitate a more direct comparison between serious adverse events (SAEs) and therapeutic benefits, we stratified those SAEs that resulted in medication interruption or discontinuation that occurred before a primary outcome event within the first 4 years of follow-up (Fig. 2) . This figure shows a clear increase in the ratio of the benefits to the side-effects of therapy as risk increases.
Our reduced model retained predictive value with a c-statistic of 0.623 (Table 4) , compared with 0.635 with the full model (Table 3 ). This suggests that these easily attainable parameters can be used in various clinical settings to predict risk of BPH progression. Clinical decision tools were then constructed from these models (Appendix 2 and Fig. 3 ).
Discussion
While MTOPS reported an overall incidence of clinical progression of 17% in the placebo group, we showed that this risk is variable among men. Whereas benefits of medical therapy for patients with a high risk of progression are clear, the benefits to patients at lower risk are less so, and may be more finely balanced with risks and sensitive to patient preferences.
Prior studies have offered several predictive baseline factors for the clinical progression of BPH. These have included increased symptom severity (both AUA-SI and BII), low Qmax, high PVR, high prostate volume, and high serum PSA level [8, 9, 19, 20, 26] . Age has also been reported to have prognostic value [6] . Similar to these previous reports, we found several predictive characteristics, including age, serum PSA level, PVR, Qmax, BII score, and AUA-SI score.
Of note, the AUA-SI score has a HR <1 in our model, indicating that higher symptoms are protective against progression. This is probably because those men with severe symptoms were less likely to progress to even worse symptoms (as detected by the AUA-SI) during the follow-up period.
In our final model, prostate volume was not necessary to yield optimal prognostic information. While seemingly in contrast to prior studies [6, 10, 26, 27] , which suggested that larger prostate volumes are associated with higher risk of BPH progression, our multivariable analysis suggests that once PSA level and symptom severity score are included, the information gained from knowing prostate size was no longer statistically significant in predicting BPH progression. This finding is particularly relevant in the primary care setting, where the availability of prostate ultrasound to measure size is uncommon. Of note, our findings cannot be generalised to men outside the MTOPS entry criteria.
Prior analyses [6, 27, 28] suggested that elevated serum PSA level and higher total prostate volume were the strongest predictors of BPH progression. The present analysis suggests that focusing on these two factors in isolation would fail to capture the entire clinical picture for a given patient. As one can imagine, in patients who have conflicting characteristics, decisions made on a single factor may inappropriately guide therapy. Moreover, univariable analyses tend to highlight a certain threshold (e.g., a patient's prostate is considered enlarged if it is >30 mL), but such decision points can arbitrarily endorse treatment or no treatment again for the non-ideal candidate.
Using our present derived nomogram will allow clinicians to account for the key factors that have been shown to predict disease progression in a large, prospective clinical trial. A patient's age, AUA-SI score, BII score, and serum PSA level can easily be collected during a clinical encounter. These values can then be translated into a 'Total Points' within our nomogram, as described in Fig. 3 , and ultimately into a risk of progression. Clinicians can then weigh this risk of progression against the potential risk of side-effects, as briefly outlined in Fig. 2 , and other patient-specific characteristics (e.g., patient compliance, medication costs to the patient). We hope to ultimately translate this nomogram into a user-friendly, web-based application.
Other groups have created clinical tools in an effort to help physicians most effectively employ medical therapy for BPH. Additionally, Slawin et al. [8, 15] performed secondary analysis on three 2-year, multicentre, placebo-controlled, double-blind randomised trials with dutasteride to create a clinical nomogram for the risk of acute urinary retention or BPH-related surgery. However, those data were limited to men with larger prostates (>30 mL) and had a shorter follow-up time than MTOPS (2 years vs 4.5 years). Moreover, MTOPS showed, in a more inclusive sample, that progression predominantly manifests as worsening symptom severity as opposed to retention or surgery. As such, the Slawin model can assist in more specialised, second-line settings, while our present model may be more widely applicable to the treatment-naïve population. Additionally, while they examined the variable risk of progression, ours remains the first study to examine combined medical therapy in a risk-stratified analysis.
Clinical decisions must also consider the AEs of possible interventions. For those men in MTOPS who received active therapy, 27% stopped doxazosin, 24% stopped finasteride, and 18% stopped combined therapy. Medication cessation was most often because of AEs [6] . We found that the risk of medication discontinuation was relatively stable across quartiles of progression risk, at 8-15%. Clinicians can use our present decision tool to weigh a patient's risk of progression against this risk of discontinuation to determine if there may be a realised benefit in initiating medical therapy.
As with most statistical models, our present findings may be subject to over-fitting and would benefit from external validation in another cohort. However, by basing our model on just a handful of clinically relevant variables and by having a large number of outcome events for each variable tested, over-fitting is less likely to have impacted our primary conclusions, although miscalibration to the external population could affect the benefits of using the model. Additionally, for methodological reasons, we excluded therapy from our model, which lowered the c-statistic; inclusion would have greatly improved discrimination, as the medications were so effective. Furthermore, while we postulated that our findings might improve effectiveness of these pharmacological interventions at the population level, no cost data were collected in the MTOPS trial, so cost-effectiveness analyses were not performed here.
In conclusion, the risk of BPH progression is highly variable among men. MTOPS data suggests that the benefits of medical therapy for BPH are unevenly distributed with men who were in the highest risk strata accounting for the greatest clinical benefit. Importantly, using commonly available baseline risk factors permits estimation of the patient-specific risk for clinical progression, and thus the potential for benefit. Our present novel decision tool based on clinically available factors (age, AUA-SI score, BII score, serum PSA level) may allow clinicians to better select those most likely to benefit from medical therapy for BPH and potentially inform future guidelines. Potential treatment effect can then be weighed against possible risks of AEs for a given patient.
Full Model -Clinical decision tool for predicting 4-year risk of clinical BPH progression using data from MTOPS. In order to determine an individual's risk of progression, draw a vertical line from each of the patient's factors to the 'Points' line above. Add the six 'Points' values together to arrive at a 'Total Points' . Calculate the expected event rate with therapy by applying the hazard ratios below. 
